Melissa Hardy

PhD Candidate, University of Queensland.

[Melissa Hardy @Merlo1969]

The win ratio method was applied post-hoc to outcomes observed in the MERINO trial with a hierarchical composite endpoint of all-cause mortality, microbiological relapse and secondary infection

[ADVANCE-ID Network @ADVANCE__ID]

👇Now available online in #CID
ADVANCE-ID: Conducting Innovative Clinical Trials and Promoting Access for Antibiotics in Asia (Vol. 82, Supplement 5; 15 June '26)

A timely collection of papers on antibiotic evidence generation and access in Asia.

🔗Link: https://t.co/MjsQznVCgq

[Data & Statistical Science for Health, LSHTM @LSHTM_datastats]

👨‍🔬 👩‍🔬 Are you working in epidemiology, clinical trials or research using target trial emulation (TTE)?

Why don’t you join us for our symposium exploring the latest methodological developments and applications of TTE and other frameworks?

Sign up 🔽
https://t.co/mpBGNWc7Id

[Melissa Hardy @Merlo1969]

@BradSpellberg @drpeterlange https://t.co/Fq43Sf0BRB

[Justin Beardsley @_jbeardsley_]

🦠 Our new paper highlights cost and access barriers to antifungals in Vietnam.

Annual drug costs for major IFIs are $209.1M, so it’s vital to get these right.
👇🏻
✅ Cost-effective procurement 💵
✅ antifungal stewardship 💊

https://t.co/OOY36EJPCa

#AMS #mycology @Sydney_ID

[INFEX Therapeutics @INFEX_TX]

Read the latest article from Professor Dame Sally Davies (UK Special Envoy on AMR) and Nikolaj Gilbert (President & CEO of PATH).

There is a looming antibiotic emergency, and the time for global action is now:
https://t.co/8vhcEpUFJO

[ADVANCE-ID Network @ADVANCE__ID]

Exciting news! 🎉 NUS launches its Master's in Infectious Disease Emergencies in July/Aug 2025. Tailored coursework, hybrid learning, and networking opportunities await! Make an impact! 🌍💼 Register here👉https://t.co/RyE7d1o1NO

#InfectiousDiseases #NUS

[Melissa Hardy @Merlo1969]

Whilst functionality and interpretation of both approaches differ, the use of a rank-based composite endpoint can provide more insights into treatment effect than a single binary endpoint i.e. mortality

https://t.co/dnSGygN98P

@davidantibiotic @padstamundo #UQCCR @MerinoTrial

[Melissa Hardy @Merlo1969]

Curious 🤔about how rank-based composite endpoints i.e. Desirability Of Outcome Ranking (DOOR) and Generalised pairwise comparison (GPC) compare in antimicrobial clinical trials? 1/6 🧵

[Melissa Hardy @Merlo1969]

We demonstrated and compared the DOOR and GPC approaches with a post hoc analysis of the MERINO 🐑trial. We highlight the advantages, challenges and potential application in antimicrobial trials. 5/6

[ADVANCE-ID Network @ADVANCE__ID]

🌍💡 Join us to design the next version of ACORN2 and ACORN-HAI by taking a 3-minute survey!! Have your say by end of October. Your input is invaluable! 🛑🦠💊 #AMR #AntimicrobialResistance #HealthcareInnovation 💻📊

👉 https://t.co/jXFn5ZrVqd

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕️⚡️⚡️Exploring desirability of outcome ranking & generalised pairwise comparisons as endpoints in serious infections: Post hoc application/MERINO
The application of DOOR & GPC approaches in this post hoc demonstrated superiority of mero over pip tazo
https://t.co/CQ7E2GHOJC

[Clinical Infectious Diseases @CIDJournal]

Win Ratio Analyses of Piperacillin-Tazobactam Versus Meropenem for Ceftriaxone-Nonsusceptible Escherichia coli or Klebsiella pneumoniae Bloodstream Infections: Post Hoc Insights From the MERINO Trial

https://t.co/y43lAVd6gy

[Melissa Hardy @Merlo1969]

@MGilchrist123 @b_fekade @BSACandJAC @jasonroberts_pk @CRE_RESPOND @raseaton66 Well done @b_fekade

[Melissa Hardy @Merlo1969]

@MGilchrist123 @b_fekade @jasonroberts_pk @raseaton66 @jamiesonce Congrats @b_fekade, @jasonroberts_pk and team. So amazing to see this finally published.

[Mark Gilchrist @MGilchrist123]

Great to see this - Evaluation of stability of ceftazidime/avibactam in elastomeric infusion devices used for OPAT. 🇬🇧 & 🇦🇺 partnership in this space continues ⁦⁦@b_fekade⁩ ⁦@jasonroberts_pk⁩ ⁦@raseaton66⁩ ⁦@jamiesonce⁩ & more https://t.co/8MPDMuoggs

[Melissa Hardy @Merlo1969]

AMR challenges RCT's which are critical to provide evidence in clinical decision making. We applied the win ratio method post hoc to the MERINO trial to provide more evidence and insights in ID trials. https://t.co/okHVPsMP4I @davidantibiotic @padstamundo @InfectiousMoYin

[Melissa Hardy @Merlo1969]

Very privileged to be a part of “Making Waves” which will air on @SBSVICELAND in celebration of International Women’s Day, friday 8th March, 9.25pm https://t.co/jelevqvjhp